Clinical trialNCT05753722RecruitingPhase 1Interventional

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

SponsorIncendia TherapeuticsEnrollment270Advanced or Metastatic Solid TumorsNSCLCNon Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joseph Paul Eder, MD
Incendia Therapeutics
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honor Health Research Institute
Scottsdale, Arizona, United States
Frank Yung-Chin Tsai, MD
Recruiting
Yale Cancer Center
New Haven, Connecticut, United States
Patricia LoRusso, DO
Recruiting
Mass General Cancer Center
Boston, Massachusetts, United States
Aparna Parikh, MD
Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon, United States
Rachel Sanborn, MD
Recruiting
University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Completed
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Jordan Berlin, MD
Recruiting
Next Houston
Houston, Texas, United States
Jennifer Segar, MD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Funda Meric-Bernstam, MD
Recruiting
Next Oncology
Irving, Texas, United States
Shiraj Sen, MD, PhD
Recruiting
Next Oncology
San Antonio, Texas, United States
David Sommerhalder, MD
Recruiting
Next Oncology
Fairfax, Virginia, United States
Alex Spira, MD,PhD,FACP
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PRTH-101Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Mar 2023
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 23 Feb 2026
Registered enrollment: 270
Registry id: NCT05753722

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.